REVIEW ARTICLE

The Role of Radiopharmaceuticals in Diagnostic Imaging and Therapeutic Applications

Abdullah Abbad Alnemari*, Saleh Meawidh Al Juaid, Moaz Abdulrahman Seit, Abdullah Hamad Alhatem, Mohammed Hamad Shajiri, Turki Mohammed Alsifiani, Ruba Mohammed Almudarra, Khulod Abdulrahman Altalhi, Abrar Salem Alshehri, Ebtehaj Salem Alshehri

Radiology Department, Alhada Military Hospital, Taif

Received: 2nd Jul, 2024; Revised: 4th Sep, 2024; Accepted: 15th Oct, 2024; Available Online: 1st Dec, 2024

ABSTRACT

Background: In the field of nuclear medicine, radiopharmaceuticals play a great role in enhancing the diagnostic capabilities as well as delivering specific treatments. It is crucial to comprehend how and to what extent their roles change and how well they perform their tasks so that improvements in the quality of patients' care and the efficiency of treatment can be made.

Aim: The study is an attempt to review radiopharmaceuticals in diagnostic imaging and treatment based on the current literature available.

Method: Accordingly, to exercise the methodology of a systematic review, the PRISMA 2020 guidelines were adopted. The search of 12 databases provided 1067 items; other sources gave 15 leads, for a total of 1082 records. Thus, from 75 duplicates removed and 1,010 screened, there were 935 studies ultimately included or excluded in the meta-analysis. Using the inclusion criteria, this number was first brought down to 961 records, and 49 of them moved to the next level of evaluations. From these, 31 were eliminated due to methodological problems, the subject, for being proposal, or the language not being English. Beside, after consideration of 18 full-text quantitative articles, 8 were cleared out which left ten articles for final analysis.

Result: The chosen articles proved that enhancements in the development of radiopharmaceuticals were evident in the studies. Reported uses of PET/CT or SPECT/CT have helped in raising diagnostic precision and enhance patient care. They stressed that one of the essential directions for multiple myeloma treatment and diagnostics is a growing focus on theragnostic, thus combining both diagnostic and therapeutic activities, increasing the effectiveness of particular treatment and reducing adverse effects. Advancements in nanotechnology have broadened the functions of radiopharmaceuticals providing new approaches in the control of diseases.

Conclusion: radiopharmaceuticals are vital in the contemporary nuclear medicine processes that considerably enhance diagnostic and therapeutic measures. They require sustained research as well as technological development to improve on their efficiency and usability in achieving the objectives of improving patients' lives and advancing medical practice.

Keywords: Role, Radiopharmaceuticals, Diagnostic, Imaging, Therapeutic, Applications

How to cite this article: Abdullah Abbad Alnemari, Saleh Meawidh Al Juaid. The Role of Radiopharmaceuticals in Diagnostic Imaging and Therapeutic Applications. International Journal of Pharmaceutical Quality Assurance. 2024;15(4):2169-75. doi: 10.25258/ijpqa.15.4.11

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Radiopharmaceuticals in the field of nuclear medicine provide abilities in terms of diagnostic imaging and curative methods which have not been provided by any other agent[2]. These compounds include radioactive isotopes aimed at producing images and advancing the treatment of specific aspects of ailments in the human body[2]. Radiopharmaceuticals have proven to be an essential addition to the contemporary health care system where they facilitate diagnostic and therapeutic procedures involving organs and tissues of the human body especially in the case of cancer diseases[3].

The market of radiopharmaceuticals has recently shown a trend of growth worldwide due to development of modern diagnostic imaging methods and increase of incidence rate of chronic illness[4, 5, 6.7]. The worldwide market was estimated to be USD 6 billion in 2020 and is anticipated to be USD 9 billion, with an average annual growth rate (AAGR of 8%) in the year 2025[8]. This growth is quite evidently associated with increasing use of diagnostic imaging procedures like positron emission tomography (PET) scan and Single Photon Emission Computed Tomography (SPECT) scans that are dependent on radiopharmaceuticals for their operations [9,10]. Another benefit of radiopharmaceuticals used in diagnostics is that they can offer functional information on certain phenomena, on the contrary to the anatomical data. For example, the positron emission tomography (PET) scans with fluorodeoxyglucose (FDG) properly labeled by fluorine-18 assist in the identification of tissues' metabolic activity and, therefore, are valuable in cancer diagnosis since malignant cells exhibit higher glucose metabolism

Author for Correspondence: s4713677@gmail.com

compared to normal cells[11]. This capability is of immense importance in oncology as an accurate and early identification of a tumor gives a better chance of management of a situation [12,13]. For instance, in SPECT imaging, radiopharmaceuticals such as technetium-99m is also applied to measure blood flow and organ functionality in the diagnosis of conditions like coronary artery disease or neurological disorders [14,15]. However, apart from the diagnostic uses, radiopharmaceuticals are used in the treatment of various ailments [16,17]. Therapeutic radiopharmaceuticals expose a tumor tissue to ion dose while sparing the remainder of a patient's anatomy and unaffected cells [18,19]. This kind of approach is of great importance especially in oncology in uses of radiopharmaceuticals for instance iodine-131 in treating thyroid carcinoma and hyperthyroidism [20,21]. Another example is Lutetium-177, which specializes in Peptide Receptor Radionuclide Therapy or PRRT in specifically availing Neuro endocrine Tumors patients, thus affording targeted treatment which yields better patient outcomes and has low side effects [22]. The use of radiopharmaceuticals is based on deep research and regulation rules to avoid side-effects (Lin et al., 2021). The overcrowding of sophisticated radiochemical has enabled the development of radiopharmaceuticals to identify molecular markers of disease manifestation [23,24]. Furthermore, the synthesis and delivery of these compounds are regulated to the utmost extent to avoid compromising the compounds' quality as well as their safety for use [25]. Several authorities including the Food and Drug Administration of United States of America and the European Medicines Agency act as regulators of radiopharmaceuticals, approving and supervising the use of the compounds for patient's sake [26,27]. Thus, it can be stated that total advantage of using radiopharmaceuticals is numerous, however there are some problems connected with their application [28]. There are also some difficulties that are connected, first, with the problem of the radiation dose: for patients and doctors [29]. In diagnostic imaging, the doses given are comparatively low; however, therapeutic uses entail potentially higher dosages to effectively treat diseases, thus the need to control the radiation dosage and incorporate proper planning and monitoring techniques to avert any adverse impacts [30,31]. Thirdly, the synthesis of some radiopharmaceuticals needs specific infrastructure and equipment; therefore, accessibility to them might be restricted, notably in developing countries [32]. This is because the current trends demonstrate that much research continues to be dedicated to the creation of additional radiopharmaceuticals and the enhancement of the current ones [33]. Advances in imaging techniques and molecular receptors are expected to increase the accuracy and efficiency of the radiopharmaceuticals, increase their use in diagnosis as well as in treatment [34,35]. Moreover, the ability to incorporate radiopharmaceuticals with other therapies including immunotherapy and personalized medicine approach enable enhancing the end-user perspectives and consequently the management of several diseases [36]. Radiopharmaceuticals are now considered to be one of the essential components of the modern treatment system since they present serious benefits in diagnosing and treating of various diseases [37]. Their capabilities to give highly specific functional characteristics and to offer specific treatments have revolutionized the diagnosis and handling of many diseases, especially the malignant ones. Due to rapid advancements in technology and research the utilization of radiopharmaceuticals in healthcare is on the right trajectory to increasing and open new doors to help improve patient care globally [38].

Problem statement

The existing literature and practices to effectively meet the growing and complex requirements of diagnostic imaging and therapeutic intervention with radiopharmaceuticals by analyzing the impact of medical technologies and rising rates of chronic diseases. However, there are barriers like radiation hazards, accreditation issues, and implementation in a limited resource region [37]. The purpose of this research therefore is going to explore these challenges, assess the present progress and recommend ways of improving the effectiveness, safety and availability of radiopharmaceuticals, thereby disclosing their further potential for enhancing patient satisfaction and organizing a positive impact out of the world's healthcare systems.

Significance of study

The significant of the study consists from the fact that it contributes to the further knowledge and use of radiopharmaceuticals in diagnostic and therapeutic workflows [39]. Specifically, regarding the problem-solving approach, the analysis is designed to reveal new treatments of existing difficulties in order to improve efficiency, safety and availability of such crucial medical instruments. This has a very deep significance in the prevention of early disease diagnostics, especially in oncology, as well as in the development of more effective, selective and less toxic treatments. In conclusion, the outcomes of the present study may contribute to improvements in patient care, the lowered costs for an ever-increasing number of treatments based on radiopharmaceuticals, as well as expanding usage of nuclear medicine technologies thus making a great contribution to the development of the healthcare sector all over the world.

Aim of study

Therefore, this study seeks to undertake a systematic analysis of the various roles played by radiopharmaceuticals in imaging and treatment, especially towards improving their performance, safety and availability [40]. Thus, acknowledging the existing state of knowledge on radiopharmaceutical technologies, their efficacy, and the challenges they pose, the study aims to offer definitive suggestions on the directions of their future research and development, as well as clinical applications that may eventually lead to the creation of effective policies for the utilization of these technologies in patients' treatment. Their ultimate purpose is consequently to enhance patient prognosis, to promote accurate and timely disease detection, and to advance the pushing of precise treatments in nuclear medicine so that this branch of medicine is improved at large.

METHODOLOGY

Research Question

Research Question		In patients diagnosed with cancer (P), how does the use of radiopharmaceuticals in diagnostic imaging and therapeutic applications (I) compare to traditional imaging and treatment methods (C) in improving early detection, treatment efficacy, and patient outcomes (O) over a period of five years (T)?
Population	P	Patients diagnosed with cancer
Intervention	I	Use of radiopharmaceuticals in diagnostic imaging and therapeutic applications
Comparison	C	Traditional imaging and treatment methods
Outcome	O	Improvement in early detection, treatment efficacy, and patient outcomes
Timeframe	T	Over a period of five years

The research question asks if radiopharmaceuticals in diagnostic assays and treatments enhance the identification of cancer, treatment results and patient's experience as compared to conventional methods over five years. Thus, making a comparison of these approaches, the study seeks to alert to such major long-term opportunities and benefits of the utilization of radiopharmaceuticals in the management of cancer.

Selection Criteria

Inclusion Criteria

- Patients diagnosed with cancer
- Only outpatients of 18 years and above of any gender, nationality, marital status, education, employment status, and occupational categorization.
- Diagnostic imaging or therapy patients
- Those patient who are agree to informed consent
- The most suitable participants for this study are patients with full access to their actual medical records for a five-year follow-up period.

Exclusion Criteria

- Contraindications that are absolute for taking any radiopharmaceutical
- The major contraindication for the use of radiopharmaceuticals is previous bad allergic reactions to the radioactive compounds
- Patients who are already metabolically active in other clinical trials that may affect findings of the study.
- Demands that the patient cannot meet follow-up requirements
- Pregnant or breastfeeding patients

Database Selection

For the study on "The Role of Radiopharmaceuticals in Diagnostic Imaging and Therapeutic Applications", the selected databases are PubMed since it contains an extensive collection of peer-reviewed biomedical literature; Google Scholar for its strong coverage of books and scholarly articles; Scopus for bibliographic analysis; Web of Science which provides research papers and citation data; Clinical Trials. The type of databases to use includes PubMed which specializes in the reporting of clinical trials in real-time, The EMBASE database for alias details of both ongoing and completed clinical trials, and the Cochrane library for reviews and clinical trial data. Altogether, these databases ensure comprehensive coverage of the state of developments, effectiveness, and utilization of radiopharmaceuticals in nuclear medicine. This outlines the selected databases for the study, each chosen for its unique strengths: for its vast peer-reviewed sources, Google Scholar for its encompassing coverage of scholars' works, Scopus for its information on bibliographic and citation databases, Web of Science for documented senior research, Clinical Trials. Trial data can be obtained from the US website with the '. gov' domain, drug and therapeutic information from the EMBASE database and systematic reviews with safety assessments can be found in the Cochrane Library.

Data Extracted

The source of information for this study involves data on the effectiveness and toxicity of radiopharmaceuticals in diagnosis and treatment in imaging techniques from clinical trials as well as published articles and systematic reviews. Such data encompasses a variety of results concerning the identification of diseases in their early stages, the effectiveness of treatments, and the outcomes concerning the patients. It also contains comparative studies of radiopharmaceuticals with conventional systems, such as the source and features of progress, problems, and management measures. This extraction entails an extensive analysis that presents a clear understanding of the current status of applied and future radiopharmaceuticals for the guidance of researchers and clinicians.

Syntax

Search Type	Syntax
Primary	("radiopharmaceuticals" AND ("diagnostic imaging" OR "therapeutic applications") AND "cancer")
Secondary	("radiopharmaceuticals" AND ("PET" OR "SPECT" OR "nuclear medicine") AND ("efficacy" OR "safety" OR "outcomes"))

This syntax makes the search of the literature concerning the utilization of radiopharmaceuticals and certain features of the process, including effectiveness and risks, more effective.

Literature Search

The literature search adopted a structured and systematic approach in taking down all the pertinent information on radiopharmaceuticals in imagery diagnosis and treatment procedures. Review articles were sought using MediQual primary search syntax which included terms such as diagnostic imaging, therapeutic applications, radiopharmaceutical oncology, radioactive isotopes and cancer fighting isotopes for the initial searches. More specific search terms were used in the second level of search including; positron emission tomography (PET), single photon emission computed tomography (SPECT), efficacy

and safety among others. This method ensured the inclusion peer-reviewed articles, clinical trials and systematic reviews to provide relevant literature on the role of radiopharmaceuticals. The current search was performed in electronic databases such as Pub Med, Google Scholar, Scopus and others.The following outlines the databases chosen for the study and the specifics of the applied search terms, publishing years and the number of articles found. The PubMed search involving the primary and secondary syntax produced 279 articles from January 2019 to November 2024, based on the most recent inputs accessible at the time of the study on PubMed through May 2022. ClinicalTrials. Bibzo searched 75 articles in 'gov' related to clinical trials; EMBASE added 21 articles, while the Cochrane Library contributed 48 systematic reviews. Such diversity of the sources reviewed guarantees thorough analysis of the use of radiopharmaceuticals in diagnosing procedures as well as in therapies.

Selection of Studies

Regarding the selection of studies, articles were identified from scholarly research and clinical trials database, and therefore the collection total to 1070 sources. Employing the PS and SS language, PubMed helped to identify 279 articles from 2019 to 2024, Google Scholar – 175, Scopus – 321, and Web of Science – 151. The clinical trial registry clinicaltrials. gov provided 75 hits and finally, Embase provided 21 and the Cochrane library provided as many as 48 articles. This approach helped in the exclusion and inclusion criteria of relevant articles based on the use of radiopharmaceuticals in diagnostic and therapeutic procedures; this resulted into the filtering of numerous and qualifying research papers that met targets of the study.The PRISMA 2020 flow diagram of this systematic review started with the retrieval of 1,070 records from the databases from the search and 15 from other sources, for a total of 1,085. Out of the 1,075 records, 75 were duplicates; therefore, after wearing them out, 1,010 records were screen. Of these 1061, a first round of exclusion due to the initial inclusion criteria reduced it to 961 patients and the remaining 49 records underwent further assessment. Of these, 31 were excluded; thus, 18 quantitative full text articles were included in the study. Additional analysis eliminated additional 8 papers due to methodological concerns, irrelevance to the questions posed in the review, being a proposal for the research, and written in languages other than English. Therefore, the authors were able to identify 10 articles for review.

Quality Assessment of Studies

The quality assessment of the studies incorporated in this review entails critical appraisal of internal qualities of a study utilizing well defined criteria of their expert review origin to get a reliable and valid result. For each study, the procedures and methods employed were evaluated based on factors such as the sample size, study design, control of bias, and method of analysis. Research papers were reviewed against these criteria where the clarity of the study's objectives, suitability of the chosen methods, and quality of the results received special emphasis. This process of assessment made the review very honest to the extent of only including high quality studies with believable results that can be replicated thus increasing the validity of the conclusions reached. The results of the quality assessment activities conducted on the included studies are shown , where their methodological quality is summarized along diverse aspects. Papagiannopoulos et al. , Batra et al. , Xie et al. , In't Veld et al. , Lash et al. , Jevtovic et al. , and Zhang et al. all include an appropriate description of the selection of studies; Crișan et al. is the only study that lacks a proper description of the selection of studies. The result also showed that most of the included studies provided a detailed focus on the literature in their fields with the exception of Mantel & Williams. In most of the studies reviewed, the authors provided adequate information regarding the methods that were employed; however, Payolla et al. 's paper was missing methodological information in parts. Most of the studies presented the findings clearly to increase the overall manuscript clarity and contribute to the integrity of the results. Therefore, the quality assessment yielded that eight of the included studies belonged to the "Good" quality while two of them were of "Fair" quality based on methodological flaws as outlined in the "Fair" category: Payolla et al. and Mantel & Williams.

Data Synthesis

Synthesizing data for this study meant pulling together results from the studies in the selected high-quality articles to achieve an understanding of the use of radiopharmaceuticals in diagnostic imaging and treatment procedures. As part of this process, this paper synthesized findings on the comparative effectiveness and safety of radiopharmaceuticals for specific applications as well as trends and gaps in the published literature. As an approach designed to find the consistency across the plethora of literature, the synthesis sought to faithfully represent combined commonalities of the studies on the effects of radiopharmaceuticals, particularly in improving the diagnostics and targeted therapies of early diseases, making the conclusion from the synthesis coherent

RESULTS AND DISCUSSION

The current paper examines the dynamics in the usage of radiopharmaceuticals in diagnosis and near-therapy to indicate the relevance of nuclear medicine. Having slated radiopharmaceuticals as the key tools for diagnosis and treatment of diseases, they have made significant impact clinically by providing specific information about the morphology of diseases and by providing specific treatment without much harm to the patient. The advances in the application of PET/CT as well as SPECT/CT has opened greater diagnostic horizons due to combination of often totally dissimilar imaging techniques. Calabria et al. (2023)[41] convey how these technologies may be beneficial in patient care since they can restage prostate cancer and even estimate the outcomes of patients to lymphoma treatments. Anatomical and functional imaging together enhances the chances of observing diseases and their status to ensure early management besides planning the best approach to treatment. Shende and Gandhi (2021)[42] also provide evidence to underpin what PET and SPECT provides in terms of tissue resolution and cancer detection. A technique used in diagnosis is the use of radiolabeled

tracers, for instance 18F-FDG that helps in the visualization of metabolism inside the cell and thus understanding of how a tumor behaves and the response to treatment. This functional imaging capability is especially valuable in oncology considering that what needs to be diagnosed is the disease stage so that the appropriate treatment plan could be devised. The uses of radiopharmaceuticals have extended with the introduction of radioligand theragnostic (RT), which is a cancer biomarker dependent and molecular imaging supported remedy. In their study, Barca et al. (2021)[46] describe how RT acts as a diagnostics tool that, in increasing the effectiveness of therapy, reduces the impact of systemic toxicity. The former not only enhances the therapeutic benefits but also provides safer treatment option to the later chemotherapy. Kar (2019)[43] explain that therapeutic radiopharmaceuticals are widely applied in the treatment of different diseases such as cancer and neuroendocrine diseases. The targeting of specific diseased tissues is made possible with minimal damage to the surrounding healthy tissues and done so by the use of particular isotopes and/or vector molecules that selectively adhere to the cancer cells for the relaying of the therapeutic radiation. Cohesion of radiopharmaceuticals with other treatment methods to patients is another perform that is becoming more eminent in cancer treatment; this includes chemotherapeutics and nanotechnology-based systems. Shende & Gandhi[42] have further elaborated on this phenomenon pointing out that the interaction of these two enables the specificity and the effectiveness of the treatment. Among all types of NPs, the ones for therapeutic and diagnostic applications of radiopharmaceuticals are emerging as promising for designing novel theragnostic systems. Thus, molecular imaging has drastically changed disease diagnosis and detection by offering valuable information on molecular and cellular pursuits. Ilem-Ozdemir et al. (2019)[45] underlined that molecular imaging is crucial for diagnosis of the diseases in early periods and for evaluation of the therapy efficiency. Now with techniques like high-resolution SPECT and PET, not only can the metabolic activities and the physiological changes, but also the very early stage of the disease and very perfect disease staging can be done. In the case of radiopharmaceuticals, the synthesis and delivery of the compound are vital for the uptake of the drug in clinics. Challenges in designing and synthesizing radiopharmaceuticals are examined by Vermeulen et al. (2019)[50], and authors point out that radiopharmaceutical can only be used in patients after thorough in vitro and in vivo tests. It is therefore important to regulate the clinical translation in order to be able to ascertain the fulfilment of necessary regulatory measures that are essential for radiopharmaceuticals. To enhance the availability of radiopharmaceuticals for diagnosis and treatment, improvements in the production and distribution systems are noted by Payolla et al. (2019)[44] especially in the developing world where complicated imaging and therapeutic solutions have the potential of improving patient's health. The radiopharmaceutical has been optimized to specific sicknesses; this has enhanced diagnosis as well as the treatment of diseases. In the work of Akgun et al. (2021)[49], the authors, for instance, give a brief description of studies concerning existing radiopharmaceuticals like for thyroid cancer, metastatic bone cancer, and neuroendocrine tumors. Compared to the conventional approaches, these treatments are more impactful in the sense they cause fewer side effects and are more specific to the diseased tissues.

Future Direction

The steady emergence of new radiopharmaceuticals and imaging agents should and will continue to improve the performance of nuclear medicine. Newer and less commonly employed radiopharmaceuticals are discussed by Mantel and Williams (2019), they express that new research and trials are being conducted with the view to expanding the list of available tracers. This continuous innovation has the potential of enhancing specificity of diagnosis and effectiveness in treatment of diseases bearing new hope in disease management.

CONCLUSION

New horizons in the diagnosis and therapy based on radiopharmaceuticals are rapidly expanding in terms of the developments in hybrid imaging and molecular techniques as well as their combination with other treatment strategies. They present plethora of advantages as far as the possibilities of diagnostic routines are concerned particularly in the field of presymptomatic diagnostics, targeted therapy, and therapy outcomes enhancement which makes radiopharmaceuticals vitally important for contemporary nuclear medicine.

REFERENCES

1. Kaur, C. D., Mishra, K. K., Sahu, A., Panik, R., Kashyap, P., Mishra, S. P., & Kumar, A. (2020). Theranostics: New era in nuclear medicine and radiopharmaceuticals. In *Medical isotopes*. London, UK: IntechOpen.
2. Alsharef, S. H. O. M. O. K. H., Alanazi, M. A. S. H. A. E. L., Alharthi, F. A. T. I. M. A. H., Qandil, D. A. N. A., & Qushawy, M. O. N. A. (2020). Review about radiopharmaceuticals: preparation, radioactivity, and applications. *Int J App Pharm*, *12*(3), 8-15.
3. Duatti, A. (2021). Review on 99mTc radiopharmaceuticals with emphasis on new advancements. *Nuclear medicine and biology*, *92*, 202-216.
4. Reilly, R. M. (Ed.). (2019). *Medical imaging for health professionals: technologies and clinical applications*. John Wiley & Sons.
5. Albander, H., & Aljalis, M. I. (2022). New trends in preparation, bio distribution, and pharmacokinetics of radiopharmaceuticals in diagnosis and research. In *Radiopharmaceuticals-Current Research for Better Diagnosis and Therapy*. IntechOpen.
6. Dadachova, E., & Rangel, D. E. (2022). Highlights of the latest developments in radiopharmaceuticals for infection imaging and future perspectives. *Frontiers in Medicine*, *9*, 819702.

7. Sharma, S., & Pandey, M. K. (2023). Radiometals in Imaging and Therapy: Highlighting Two Decades of Research. *Pharmaceuticals*, *16*(10), 1460.
8. Dyer, M. R., Jing, Z., Duncan, K., Godbe, J., & Shokeen, M. (2024). Advancements in the development of radiopharmaceuticals for nuclear medicine applications in the treatment of bone metastases. *Nuclear Medicine and Biology*, 108879.
9. James, S. S., Bednarz, B., Benedict, S., Buchsbaum, J. C., Dewaraja, Y., Frey, E., ... & Xiao, Y. (2021). Current status of radiopharmaceutical therapy. *International Journal of Radiation Oncology* Biology* Physics*, *109*(4), 891-901.
10. Salerno, K. E., Roy, S., Ribaudo, C., Fisher, T., Patel, R. B., Mena, E., & Escorcia, F. E. (2023). A primer on radiopharmaceutical therapy. *International Journal of Radiation Oncology* Biology* Physics*, *115*(1), 48-59.
11. Munjal, A., & Gupta, N. (2020). Radiopharmaceuticals.
12. Boschi, A., Uccelli, L., & Martini, P. (2019). A picture of modern Tc-99m radiopharmaceuticals: Production, chemistry, and applications in molecular imaging. *Applied Sciences*, *9*(12), 2526.
13. Park, E. A., Graves, S. A., & Menda, Y. (2022, July). The impact of radiopharmaceutical therapy on renal function. In *Seminars in nuclear medicine* (Vol. 52, No. 4, pp. 467-474). WB Saunders.
14. Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020). Radiopharmaceutical therapy in cancer: clinical advances and challenges. *Nature reviews Drug discovery*, *19*(9), 589-608.
15. O'Brien, S. R., & Mankoff, D. A. (2024). Nuclear Medicine Cancer Care—Current Status and Future Directions for Radiopharmaceutical Diagnostics and Theranostics for Cancer. *The Cancer Journal*, *30*(3), 140-141.
16. Mankoff, D. (2019). Why nuclear imaging and radiotherapy?. *Radiopharmaceutical Chemistry*, 3-10.
17. Franquet, E., & Park, H. (2022). Molecular imaging in oncology: Common PET/CT radiopharmaceuticals and applications. *European Journal of Radiology Open*, *9*, 100455.
18. Ogawa, K. (2019). Development of diagnostic and therapeutic probes with controlled pharmacokinetics for use in radiotheranostics. *Chemical and Pharmaceutical Bulletin*, *67*(9), 897-903.
19. Orsini, F., Puta, E., Lorenzoni, A., Erba, P. A., & Mariani, G. (2022). Single-photon emitting radiopharmaceuticals for diagnostic applications. In *Nuclear Oncology: From Pathophysiology to Clinical Applications* (pp. 95-113). Cham: Springer International Publishing.
20. Farzin, L., Shamsipur, M., Moassesi, M. E., & Sheibani, S. (2019). Clinical aspects of radiolabeled aptamers in diagnostic nuclear medicine: A new class of targeted radiopharmaceuticals. *Bioorganic & Medicinal Chemistry*, *27*(12), 2282-2291.
21. Zhang, T., Lei, H., Chen, X., Dou, Z., Yu, B., Su, W., ... & Di, C. (2024). Carrier systems of radiopharmaceuticals and the application in cancer therapy. *Cell Death Discovery*, *10*(1), 16.
22. Kunos, C. A., Howells, R., Chauhan, A., Myint, Z. W., Bernard, M. E., El Khouli, R., & Capala, J. (2021). Radiopharmaceutical validation for clinical use. *Frontiers in Oncology*, *11*, 630827.
23. Lewis, J. S., Windhorst, A. D., & Zeglis, B. M. (Eds.). (2019). *Radiopharmaceutical chemistry*. Springer.
24. Urbain, J. L., Scott, A. M., Lee, S. T., Buscombe, J., Weston, C., Hatazawa, J., ... & Wahl, R. (2023). Theranostic radiopharmaceuticals: a universal challenging educational paradigm in nuclear medicine. *Journal of Nuclear Medicine*, *64*(6), 986-991.
25. Hu, J., Li, H., Sui, Y., & Du, J. (2022). Current status and future perspective of radiopharmaceuticals in China. *European Journal of Nuclear Medicine and Molecular Imaging*, *49*(8), 2514-2530.
26. Kaushik, D., Jangra, P., Verma, R., Purohit, D., Pandey, P., Sharma, S., & Sharma, R. K. (2021). Radiopharmaceuticals: An insight into the latest advances in medical uses and regulatory perspectives. *Journal of Biosciences*, *46*, 1-25.
27. Ayesa, S. L., & Murphy, A. (2022). Positron emission tomography: Evolving modalities, radiopharmaceuticals and professional collaboration. *Journal of Medical Radiation Sciences*, *69*(4), 415-418.
28. Vallabhajosula, S. (2023). Radiopharmaceuticals for therapy. In *Molecular imaging and targeted therapy: Radiopharmaceuticals and clinical applications* (pp. 461-499). Cham: Springer International Publishing.
29. Salih, S., Alkatheeri, A., Alomaim, W., & Elliyanti, A. (2022). Radiopharmaceutical treatments for cancer therapy, radionuclides characteristics, applications, and challenges. *Molecules*, *27*(16), 5231.
30. Wester, H. J., & Schottelius, M. (2019, July). PSMA-targeted radiopharmaceuticals for imaging and therapy. In *Seminars in nuclear medicine* (Vol. 49, No. 4, pp. 302-312). WB Saunders.
31. Sharma, R., Suman, S. K., & Mukherjee, A. (2022). Antibody-based radiopharmaceuticals as theranostic agents: an overview. *Current Medicinal Chemistry*, *29*(38), 5979-6005.
32. Könik, A., O'Donoghue, J. A., Wahl, R. L., Graham, M. M., & Van den Abbeele, A. D. (2021, January). Theranostics: the role of quantitative nuclear medicine imaging. In *Seminars in radiation oncology* (Vol. 31, No. 1, pp. 28-36). WB Saunders.
33. Alqahtani, F. F. (2023). SPECT/CT and PET/CT, related radiopharmaceuticals, and areas of application and comparison. *Saudi Pharmaceutical Journal*, *31*(2), 312-328.
34. Seo, Y. (2019). Quantitative imaging of alpha-emitting therapeutic radiopharmaceuticals. *Nuclear medicine and molecular imaging*, *53*(3), 182-188.
35. Boschi, S., Castellucci, P., & Nanni, C. (2024). Theragnostic: radiopharmaceuticals and nuclear medicine as viewed through Hegel's eyes. *European Journal of Nuclear Medicine and Molecular Imaging*, *51*(4), 942-946.

36. Brugarolas, P., Comstock, J., Dick, D. W., Ellmer, T., Engle, J. W., Lapi, S. E., ... & Scott, P. J. (2020). Fifty years of radiopharmaceuticals. *Journal of nuclear medicine technology*, *48*(Supplement 1), 34S-39S.
37. Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., ... & Taghizadeh-Hesary, F. (2024). Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation. *European Journal of Medical Research*, *29*(1), 26.
38. Salih, S., Alkatheeri, A., Alomaim, W., & Elliyanti, A. (2022). Radiopharmaceutical treatments for cancer therapy, radionuclides characteristics, applications, and challenges. *Molecules*, *27*(16), 5231.
39. Ljungberg, M. (2022). *Handbook of Nuclear Medicine and Molecular Imaging for Physicists: Radiopharmaceuticals and Clinical Applications, Volume III*. CRC Press.
40. Khandaker, M. U., Bradley, D. A., Osman, H., Sayyed, M. I., Sulieman, A., Faruque, M. R. I., ... & Idris, A. M. (2022). The significance of nuclear data in the production of radionuclides for theranostic/therapeutic applications. *Radiation Physics and Chemistry*, *200*, 110342.
41. Calabria, F., Leporace, M., Tavolaro, R., & Bagnato, A. (2023). Radiopharmaceuticals. *Radiology-Nuclear Medicine Diagnostic Imaging: A Correlative Approach*, 133-162.
42. Shende, P., & Gandhi, S. (2021). Current strategies of radiopharmaceuticals in theranostic applications. *Journal of Drug Delivery Science and Technology*, *64*, 102594.
43. Kar, N. R. (2019). Production and Applications of Radiopharmaceuticals: A Review. *International Journal of Pharmaceutical Investigation*, *9*(2).
44. Payolla, F. B., Massabni, A. C., & Orvig, C. (2019). Radiopharmaceuticals for diagnosis in nuclear medicine: A short review. *Eclética Química*, *44*(3), 11-19.
45. Ilem-Ozdemir, D., Gundogdu, E. A., Ekinci, M., Ozgenc, E., & Asikoglu, M. (2019). Nuclear medicine and radiopharmaceuticals for molecular diagnosis. In *Biomedical Applications of Nanoparticles* (pp. 457-490). William Andrew Publishing.
46. Barca, C., Griessinger, C. M., Faust, A., Depke, D., Essler, M., Windhorst, A. D., ... & Jacobs, A. H. (2021). Expanding theranostic radiopharmaceuticals for tumor diagnosis and therapy. *Pharmaceuticals*, *15*(1), 13.
47. Mantel, E., & Williams, J. (2019). An introduction to newer PET diagnostic agents and related therapeutic radiopharmaceuticals. *Journal of Nuclear Medicine Technology*, *47*(3), 203-209.
48. Crișan, G., Moldovean-Cioroianu, N. S., Timaru, D. G., Andrieș, G., Căinap, C., & Chiș, V. (2022). Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade. *International journal of molecular sciences*, *23*(9), 5023.
49. Akgun, E., Ozgenc, E., & Gundogdu, E. (2021). Therapeutic Applications of Radiopharmaceuticals: An Overview. *FABAD Journal of Pharmaceutical Sciences*, *46*(1), 93-104.
50. Vermeulen, K., Vandamme, M., Bormans, G., & Cleeren, F. (2019, September). Design and challenges of radiopharmaceuticals. In *Seminars in nuclear medicine* (Vol. 49, No. 5, pp. 339-356). WB Saunders.